Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

WHARTON JELLY ORIGINATED MESENCHIAL STEM CELL in GONARTHROSIS (WHAMKO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04313894
Recruitment Status : Recruiting
First Posted : March 18, 2020
Last Update Posted : March 18, 2020
Sponsor:
Information provided by (Responsible Party):
İbrahim Karaman, TC Erciyes University

Brief Summary:

Osteoarthritis (OA) is a progressive disease characterized by degeneration of the joint cartilage, which is involved in the immune system leading to proinflammatory cytokine and metalloproteinase release. Knee osteoarthritis is the most common form. The healing is very slow and the damage is not fully recovered, so the degeneration process continues and no treatment modalities completely remove this process. Various methods are used in the treatment of OA and total joint replacement is performed in the patients with OA recently.

Ten patients with Kellgren-Lawrence grade II-III knee OA who had been applied for knee pain and received conservative treatment for 6 months and had no benefit will be taken to study. Patients will be assessed 7 (V1-7) times during the study. Clinical, immunologic and radiological treatment effectiveness and clinical improvement will be evaluated at the beginning of the treatment and in all follow-up patients participating in the study.


Condition or disease Intervention/treatment Phase
Stem Cell Gonarthrosis Biological: Wharton Jelly Originated Mesencimal Stem Cell Phase 2

Detailed Description:

Osteoarthritis (OA) is a progressive disease characterized by degeneration of the articular cartilage, caused with the release of proinflammatory cytokines and metalloproteinases. Knee osteoarthritis is the most common form. OA accounts for about 2% of public health problems and leads to a reduction in production, resulting in indirect costs. Regardless of the etiology (age, trauma, overuse, autoimmune arthritis, infection, etc.), the recovery is very slow, the damage is not fully recovered, and the result is secondary fibrosis healing. Therefore, the degeneration process continues and no treatment modality does not completely eliminate this process. Various methods are used in the treatment of OA. The most commonly used of these methods are the physical and educational therapy offered by the American Society of Orthopedic Surgeons (AAOS), symptomatic treatment with acetaminophen and non-steroidal anti-inflammatory drugs, and steroid injection. In patients with end-stage OA who do not benefit from these treatment methods, total joint replacement is performed. Mesenchymal stem cells are multiple potent progenitor cells. In recent years, there have been promising developments in the treatment of patients who cannot be cured by stem cell therapy. Mesenchymal stem cells have been used in clinical and experimental animal studies due to their immunosuppressive effects, limited immunogenetic effects, their ability to be produced in culture and their multilevel structure. At the same time, studies have shown that mesenchymal stem cells have potential to differentiate into osteocytes, chondrocytes, muscle cells and nerve cells. Because of these features, mesenchymal stem cells have been used clinically for OA treatment. In addition, studies have shown that mesenchymal stem cells can be obtained from bone marrow, periosteum, trabecular bone, fat tissue, synovia, muscle tissue, milk tooth, umbilical cord and Wharton gel. Wharton gel is a mucous connective tissue in the umbilical cord and consists of myofibroblast-like stromal cells, collagen fibers, proteoglycans and hyaluronic acid. Because of these properties, it can be used as a source of stem cells.

dipocytokines are cytokines secreted from adipose tissue and act as intercellular signal proteins. These cytokines include adipose tissue and cells nutrient uptake, regulation of energy balance, insulin activation, lipid and glucose metabolism, angiogenesis, regulation of blood pressure, coagulation, immunostimulation, pro-inflammatory and anti-inflammatory effects.

Stem cell applications are now widely used in different tissues. In the recovery of chondral damage; Since cells have little capacity for regeneration and proliferation, stem cell derived differentiation is needed. In this study, it will be tried to show that chondral damage can be treated with wharton gel-derived stem cells.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: THE EFFECTIVENESS of WHARTON JELLY ORIGINATED MESENCHIAL STEM CELL in TREATMENT of KNEE OSTEOARTHRITIS
Actual Study Start Date : January 1, 2019
Actual Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Stem Cell Therapia Group
A total of 11 patients with Kellgren-Lawrence grade II-III knee OA who were admitted to the outpatient clinic with knee pain and who had received conservative treatment for a period of 6 months and who had not benefited from it will be taken. Patients will be evaluated 7 (V1-7) during the study period. Patients who comply with the study criteria will be included in the study. The clinical, immunological and radiological efficacy of the treatment and clinical improvement will be evaluated in all follow-up patients at the beginning and at the beginning of the treatment.
Biological: Wharton Jelly Originated Mesencimal Stem Cell
In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.




Primary Outcome Measures :
  1. Changing of Pain after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    Pain Evaluation With Visual Analog Scale (min : 0 - max: 10)

  2. Changing of functional knee score after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).

  3. Changing of life Quality after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    Short Form 36 (min :0 - max :100)

  4. Radiological Changings according to Kellgren-Lawrence classification systemafter Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 12 Months after injection ]
    Direct Graphy Kellgren-Lawrence classification (0-4) - (0 : Better)

  5. Chondral and subchondral Changings after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 12 Months after injection ]
    Magnetic Resosonans Imaging T2 mapping (msn): If an area have a value above 50/msn that will named as inflamated cartilage. This area's size and mean speed will be evaluated.

  6. Changing of Leptin levels in sinovial fluid after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    Leptin levels in sinovial fluid (elisa)

  7. Changing of adiponectin levels in sinovial fluid after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    Adiponectin levels in sinovial fluid (elisa)

  8. Changing of tumor necrosing factor-α levels in sinovial fluid after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    tumor necrosing factor-α levels in sinovial fluid (elisa)

  9. Changing of resistin levels in sinovial fluid after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    Resistin levels in sinovial fluid (elisa)

  10. Changing of interleukin-6 levels in sinovial fluid after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    interleukin-6 levels in sinovial fluid (elisa)

  11. Changing of interleukin-1β levels in sinovial fluid after Wharton Jelly Originated Mesenchial Stem Cell İnjection for one year [ Time Frame: Before injection and 15 Day - 30 Day - 45 Day - 3 months - 6 Months - 12 Months after injection ]
    interleukin-1β levels in sinovial fluid



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Kellgren-Lawrence Grade II-III OA
  • Between 60- 65 years old
  • Those with chronic knee pain not undergoing 6 months of conservative treatment
  • Body Mass Index: 25-30 kg / m2
  • Patients who understand the content of the study
  • Patients with written consent form

Exclusion Criteria:

  • Patients with Diabetes Mellitus
  • Patients with septic table
  • Patients with bleeding diathesis
  • Patients with HIV and Hepatitis
  • Body Mass Index greater than 30 kg / m2 and lower than 25 kg / m2
  • Those with congenital axis disorder
  • Those with malignancy
  • Immunosuppressive
  • Lumbar pathological findings

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04313894


Contacts
Layout table for location contacts
Contact: Ali E Günay, MD +905556493401 alieraygunay@hotmail.com
Contact: Ali E Günay, MD +903522076666 alieraygunay@hotmail.com

Locations
Layout table for location information
Turkey
Erciyes University Faculty of Medicine Recruiting
Melikgazi, Kayseri, Turkey, 38050
Contact: Ali Eray GUNAY, resisdent    +905556493401    alieraygunay@hotmail.com   
Contact: İbrahim KARAMAN, docent    05327183353    drikaraman@gmail.com   
Principal Investigator: Ahmet Güney, professor         
Principal Investigator: Yusuf Özkul, professor         
Principal Investigator: Mukerrem B Aycan, Assoc. prof         
Principal Investigator: Eren Demirpolat, Assist. prof         
Principal Investigator: Ali Eray Günay, Med. Doctor         
Principal Investigator: İbrahim Karaman, Assoc prof         
Principal Investigator: Zeynep B Gonen, Resident         
Principal Investigator: Ebru Ozturk, Resident         
Sponsors and Collaborators
TC Erciyes University
Investigators
Layout table for investigator information
Study Director: İbrahim Karaman, Asc.Prof TC Erciyes University
Layout table for additonal information
Responsible Party: İbrahim Karaman, TC Erciyes University - Scientific Researches Projects Support, TC Erciyes University
ClinicalTrials.gov Identifier: NCT04313894    
Other Study ID Numbers: 2015/397
First Posted: March 18, 2020    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by İbrahim Karaman, TC Erciyes University:
Gonarthrosis
Degenerative Arthritis Treatment
Stem Cell Therapia
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases